Tag: a clinical-stage biotechnology company commercializing a novel vaccination platform
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
